TherapeuticsMD, Inc.
TXMDDrugs in Pipeline
86
Phase 3 Programs
31
Upcoming Catalysts
7
Next Catalyst
This month
Market Overview
Stock performance and key metrics
7 upcoming, 0 past
IG3018 Phase 2 Est. Readout
Estimated primary completion for IG3018 trial (NCT06310967) in Hyperuricemia. Topline data typically follows completion by weeks to months.
Source6 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How TXMD's past catalysts played out
BGF MDI 320/14.4/9.6 μg
COPD
Single-Dose IV Oritavancin Diphosphate
Wound Infection
XIAFLEX / XIAPEX
Dupuytren's Contracture
Oxymorphone Extended Release
Chronic Pain
JP-1366 20mg
Erosive Esophagitis
Saroglitazar magnesium 1 mg
Non-Alcoholic Fatty Liver Disease
ETC-1002
Hypercholesterolemia
Neridronate
Complex Regional Pain Syndrome Type I
Dexycu
Inflammation
GFF MDI (PT003) 14.4/9.6 μg
COPD
Frovatriptan
Menstrually Associated Migraine
CR845
Uremic Pruritus
Botulinum Toxins, Type A
Glabellar Frown Lines
Oral Calcitonin Tablets
Osteoporosis, Postmenopausal
pagoclone
Stuttering
BFF MDI 320/9.6 μg
Chronic Obstructive Pulmonary Disorder
GFF MDI (PT003)
COPD
ACER-002 (celiprolol) 200 mg BID
Vascular Ehlers-Danlos Syndrome
Frovatriptan 2.5mg QD
Migraine
Reproxalap Ophthalmic Solution (0.25%)
Dry Eye
Frovatriptan 2.5 mg
Migraine
Human platelets
Cardiac Surgery
BGF MDI (PT010)
COPD
Estradiol
Menopause
Progesterone
Menopause
3.2 mg intranasal carbetocin
Prader-Willi Syndrome
Pegtibatinase
Homocystinuria
Loncastuximab Tesirine
Relapsed Diffuse Large B-Cell Lymphoma
delafloxacin
Skin and Subcutaneous Tissue Bacterial Infections
Saroglitazar Magnesium 2 mg
Primary Biliary Cholangitis
Tiratricol
Monocarboxylate Transporter 8 Deficiency
CT-868
Obesity
RT001 Botulinum toxin type A (Dose A)
Lateral Canthal Lines
AHB-137
Hepatitis B, Chronic
ANG003 Dose A
Exocrine Pancreatic Insufficiency (EPI)
SF0166 Topical Ophthalmic Solution
Age-Related Macular Degeneration
Eteplirsen
Muscular Dystrophy, Duchenne
Etavopivat
Sickle Cell Disease
ADX-629
Chronic Cough
BTRX-246040
Parkinson Disease
IMC-001
Extranodal NK/T-cell Lymphoma, Nasal Type
ARD-101
Bariatric Surgery
CCH-aaes
Edematous Fibrosclerotic Panniculopathy
SM04690
Osteoarthritis
EN3835
Adhesive Capsulitis
Tagraxofusp
Acute Myeloid Leukemia
AZD2115 Dose 1
Chronic Obstructive Pulmonary Disease (COPD)
anamorelin HCl
Carcinoma, Non-Small-Cell Lung
SKP-1041 (experimental formulation of zaleplon)
Sleep Disorder
RNK05047
Advanced Solid Tumor
RNK08954
KRAS G12D Mutations
RNK08954-01
KRAS G12D Mutation
Camidanlumab Tesirine
Relapsed Hodgkin Lymphoma
Triac
Allan-Herndon-Dudley Syndrome
ABSK061 + ABSK043
HER2-Gastric/Gastroesophageal Junction Cancer
ETX-018810
Diabetic Peripheral Neuropathic Pain
MSDC-0602K
Non-alcoholic Fatty Liver Disease
Collagenase clostridium histolyticum
Dupuytren's Disease
Allo-QuadCAR01-T
Lymphoma Diffuse Large B-cell
188-0551 Solution
Plaque Psoriasis
IG3018
Hyperuricemia
YL201 for Injection
Advanced Solid Tumor
5 mg Serlopitant Tablets
Pruritus
Halobetasol Propionate Lotion 0.05%
Psoriasis
OPN-305
Myelodysplastic Syndrome
Gene Therapy product:vMCO-I
Retinitis Pigmentosa
GFH018
NSCLC, Stage III
Sevuparin
Sickle-Cell Disease
SRP1020
Advanced Solid Tumors
Oral Testosterone Undecanoate
Hypogonadism
UHE-105
Scalp Psoriasis
Recombinant Human Plasma Gelsolin
Community-acquired Pneumonia
NT100
Repeated IVF Failure
XOPH5 Ointment
Lower Eyelid Steatoblepharon (Excess Eyelid Fat)
fludarabine phosphate
Accelerated Phase Chronic Myelogenous Leukemia
ABSK043 in combination with Glecirasib
Non-Small Cell Lung Cancer
PT-112
Non-Small Cell Lung Cancer (NSCLC)
DPI-386 Nasal Gel
Motion Sickness, Space
ABSK043 in combination with Firmonertinib
Non-Small Cell Lung Cancer With EGFR Mutation
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)
Adult Brain Glioblastoma
Brepocitinib
Dermatomyositis
DAXI 80 U
Plantar Fasciitis
Norketotifen
Allergic Rhinitis
LT3001 Drug Product
Acute Ischemic Stroke
ABX-002
Major Depressive Disorder
ALT-100 mAb
Acute Respiratory Distress Syndrome (ARDS)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BGF MDI 320/14.4/9.6 μg | Phase 3 | COPD | - | - |
Single-Dose IV Oritavancin Diphosphate | Phase 3 | Wound Infection | - | - |
XIAFLEX / XIAPEX | Phase 3 | Dupuytren's Contracture | - | - |
Oxymorphone Extended Release | Phase 3 | Chronic Pain | - | - |
JP-1366 20mg | Phase 3 | Erosive Esophagitis | - | - |
Saroglitazar magnesium 1 mg | Phase 3 | Non-Alcoholic Fatty Liver Disease | - | - |
ETC-1002 | Phase 3 | Hypercholesterolemia | - | - |
Neridronate | Phase 3 | Complex Regional Pain Syndrome Type I | - | - |
Dexycu | Phase 3 | Inflammation | - | - |
GFF MDI (PT003) 14.4/9.6 μg | Phase 3 | COPD | - | - |
Frovatriptan | Phase 3 | Menstrually Associated Migraine | - | - |
CR845 | Phase 3 | Uremic Pruritus | - | - |
Botulinum Toxins, Type A | Phase 3 | Glabellar Frown Lines | - | - |
Oral Calcitonin Tablets | Phase 3 | Osteoporosis, Postmenopausal | - | - |
pagoclone | Phase 3 | Stuttering | - | - |
BFF MDI 320/9.6 μg | Phase 3 | Chronic Obstructive Pulmonary Disorder | - | - |
GFF MDI (PT003) | Phase 3 | COPD | - | - |
ACER-002 (celiprolol) 200 mg BID | Phase 3 | Vascular Ehlers-Danlos Syndrome | - | - |
Frovatriptan 2.5mg QD | Phase 3 | Migraine | - | - |
Reproxalap Ophthalmic Solution (0.25%) | Phase 3 | Dry Eye | - | - |
Frovatriptan 2.5 mg | Phase 3 | Migraine | - | - |
Human platelets | Phase 3 | Cardiac Surgery | - | - |
BGF MDI (PT010) | Phase 3 | COPD | - | - |
Estradiol | Phase 3 | Menopause | - | - |
Progesterone | Phase 3 | Menopause | - | - |
3.2 mg intranasal carbetocin | Phase 3 | Prader-Willi Syndrome | - | - |
Pegtibatinase | Phase 3 | Homocystinuria | - | - |
Loncastuximab Tesirine | Phase 3 | Relapsed Diffuse Large B-Cell Lymphoma | - | - |
delafloxacin | Phase 3 | Skin and Subcutaneous Tissue Bacterial Infections | - | - |
Saroglitazar Magnesium 2 mg | Phase 3 | Primary Biliary Cholangitis | - | - |
Tiratricol | Phase 3 | Monocarboxylate Transporter 8 Deficiency | - | - |
CT-868 | Phase 2 | Obesity | - | - |
RT001 Botulinum toxin type A (Dose A) | Phase 2 | Lateral Canthal Lines | - | - |
AHB-137 | Phase 2 | Hepatitis B, Chronic | - | - |
ANG003 Dose A | Phase 2 | Exocrine Pancreatic Insufficiency (EPI) | - | - |
SF0166 Topical Ophthalmic Solution | Phase 2 | Age-Related Macular Degeneration | - | - |
Eteplirsen | Phase 2 | Muscular Dystrophy, Duchenne | - | - |
Etavopivat | Phase 2 | Sickle Cell Disease | - | - |
ADX-629 | Phase 2 | Chronic Cough | - | - |
BTRX-246040 | Phase 2 | Parkinson Disease | - | - |
IMC-001 | Phase 2 | Extranodal NK/T-cell Lymphoma, Nasal Type | - | - |
ARD-101 | Phase 2 | Bariatric Surgery | - | - |
CCH-aaes | Phase 2 | Edematous Fibrosclerotic Panniculopathy | - | - |
SM04690 | Phase 2 | Osteoarthritis | - | - |
EN3835 | Phase 2 | Adhesive Capsulitis | - | - |
Tagraxofusp | Phase 2 | Acute Myeloid Leukemia | - | - |
AZD2115 Dose 1 | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
anamorelin HCl | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
SKP-1041 (experimental formulation of zaleplon) | Phase 2 | Sleep Disorder | - | - |
RNK05047 | Phase 2 | Advanced Solid Tumor | - | - |
RNK08954 | Phase 2 | KRAS G12D Mutations | - | - |
RNK08954-01 | Phase 2 | KRAS G12D Mutation | - | - |
Camidanlumab Tesirine | Phase 2 | Relapsed Hodgkin Lymphoma | - | - |
Triac | Phase 2 | Allan-Herndon-Dudley Syndrome | - | - |
ABSK061 + ABSK043 | Phase 2 | HER2-Gastric/Gastroesophageal Junction Cancer | - | - |
ETX-018810 | Phase 2 | Diabetic Peripheral Neuropathic Pain | - | - |
MSDC-0602K | Phase 2 | Non-alcoholic Fatty Liver Disease | - | - |
Collagenase clostridium histolyticum | Phase 2 | Dupuytren's Disease | - | - |
Allo-QuadCAR01-T | Phase 2 | Lymphoma Diffuse Large B-cell | - | - |
188-0551 Solution | Phase 2 | Plaque Psoriasis | - | - |
IG3018 | Phase 2 | Hyperuricemia | - | - |
YL201 for Injection | Phase 2 | Advanced Solid Tumor | - | - |
5 mg Serlopitant Tablets | Phase 2 | Pruritus | - | - |
Halobetasol Propionate Lotion 0.05% | Phase 2 | Psoriasis | - | - |
OPN-305 | Phase 2 | Myelodysplastic Syndrome | - | - |
Gene Therapy product:vMCO-I | Phase 2 | Retinitis Pigmentosa | - | - |
GFH018 | Phase 2 | NSCLC, Stage III | - | - |
Sevuparin | Phase 2 | Sickle-Cell Disease | - | - |
SRP1020 | Phase 2 | Advanced Solid Tumors | - | - |
Oral Testosterone Undecanoate | Phase 2 | Hypogonadism | - | - |
UHE-105 | Phase 2 | Scalp Psoriasis | - | - |
Recombinant Human Plasma Gelsolin | Phase 2 | Community-acquired Pneumonia | - | - |
NT100 | Phase 2 | Repeated IVF Failure | - | - |
XOPH5 Ointment | Phase 2 | Lower Eyelid Steatoblepharon (Excess Eyelid Fat) | - | - |
fludarabine phosphate | Phase 2 | Accelerated Phase Chronic Myelogenous Leukemia | - | - |
ABSK043 in combination with Glecirasib | Phase 2 | Non-Small Cell Lung Cancer | - | - |
PT-112 | Phase 2 | Non-Small Cell Lung Cancer (NSCLC) | - | - |
DPI-386 Nasal Gel | Phase 2 | Motion Sickness, Space | - | - |
ABSK043 in combination with Firmonertinib | Phase 2 | Non-Small Cell Lung Cancer With EGFR Mutation | - | - |
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose) | Phase 2 | Adult Brain Glioblastoma | - | - |
Brepocitinib | Phase 2 | Dermatomyositis | - | - |
DAXI 80 U | Phase 2 | Plantar Fasciitis | - | - |
Norketotifen | Phase 2 | Allergic Rhinitis | - | - |
LT3001 Drug Product | Phase 2 | Acute Ischemic Stroke | - | - |
ABX-002 | Phase 2 | Major Depressive Disorder | - | - |
ALT-100 mAb | Phase 2 | Acute Respiratory Distress Syndrome (ARDS) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in TherapeuticsMD, Inc.'s drug pipeline?→
CatalystAlert tracks 86 drug candidates in TherapeuticsMD, Inc.'s (TXMD) pipeline across Phase 3, Phase 2. Its lead program is BGF MDI 320/14.4/9.6 μg (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TherapeuticsMD, Inc.'s next FDA catalyst?→
TherapeuticsMD, Inc.'s (TXMD) next tracked catalyst is a Phase 2 expected July 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TXMD biotech catalysts?→
Add TXMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TherapeuticsMD, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.